Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  News  >  Companies  >  All News

News : Companies
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors

Cobra Biologics : Receives the Queen's Award for Enterprise in International Trade

share with twitter share with LinkedIn share with facebook
04/21/2018 | 04:01am EDT

The UK’s most prestigious business award granted in recognition of outstanding achievement in the export of services for gene and immunotherapy products.

Cobra Biologics (“Cobra”) a leading international contract development and manufacturing organisation (“CDMO”), today announced that it has been awarded the Queen’s Award 2018 for Enterprise, in the International Trade category. The prestigious award is in recognition of Cobra’s commercial success in providing services to its global customer base.

Now in their 53rd year, the Queen’s Awards have a long history of recognising exceptional UK businesses and Cobra will be attending a reception at Buckingham Palace followed by a presentation of the Award by a representative of Her Majesty The Queen at Cobra’s UK facility later in the year.

Cobra has a 20 year track record of supporting the life science industry with contract development and manufacturing of biopharmaceuticals, from preclinical through to clinical trials and commercial supply and currently exports over 85% of its services from its facilities based in the UK and Sweden.

Cobra’s UK based GMP approved facility is a globally recognised centre of excellence for the development and production of biological material to support both gene- and immuno-therapy. In April 2017, Cobra announced a £15 million gene therapy expansion plan, to meet the increased demand from both plasmid DNA and viral vectors for Phase III and Commercial supply to support both existing and new customer requirements in the development of revolutionary disease therapies.

Peter Coleman, Chief Executive of Cobra Biologics, commented: “I am immensely proud of what Cobra has achieved over the last few years, culminating in the Queen’s Award. International Trade is vitally important for Cobra and the work that we do is challenging and requires a committed work force whose skills and dedication attract business from all over the world. I would like also to thank the Office for Life Science, Innovate UK and the Department for International Trade for their support of our expansion plans in the UK.”

ENDS


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
Latest news "Companies"
11:50aFlu-Like Symptoms of the ‘Great Masquerader' Could Fool You Toward Misdiagnosis of Lyme Disease, Cautions Healthy Directions
GL
11:50aReliance Standard Launches RSL Complete® Dental+Vision Benefit Plan
BU
11:49aAC&MFD Circular Letter No. 05 of 2020 - REGULATORY RELIEF TO DAMPEN THE EFFECTS OF COVID-19 - PRUDENTIAL REGULATIONS FOR AGRICULTURE FINANCING
PU
11:49aAC&MFD Circular Letter No. 04 of 2020 - REGULATORY RELIEF TO DAMPEN THE EFFECTS OF COVID-19 - PRUDENTIAL REGULATIONS FOR MICRO FINANCE BANKS
PU
11:49aGROUPE ADP : May 2020 traffic figures
PU
11:49aKEYSIGHT TECHNOLOGIES : New Test Solution Optimizes Performance of 5G Devices Using MIMO Technology to Increase Data Throughput
PU
11:47aTheodore Lipscomb named to top job at LISC Milwaukee to expand economic development investments, deepen response to COVID-19
PR
11:47aPortable Air-Conditioner Market with Impact of COVID-19 Highlights (series) | Awareness about Energy-Efficient Devices to Boost the Market Growth | Technavio
BU
11:47aVERALLIA : Result of the Option to Receive the 2019 Dividend Payment in New Shares
BU
11:47aHOFFMANN GREEN CEMENT TECHNOLOGIES : Announces That Its H-UKR Cement-related Activities Are Now Guaranteed by Insurance Company AXA
BU
Latest news "Companies"